Tracking the pharmaceutical pipeline: Clinical trials and global disease burden

Clinical and Translational Science

Volumn 7, Issue 4, 2014, Pages 297-299

  Cottingham, Marci D ^a   Kalbaugh, Corey A ^b   Fisher, Jill A ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b University of North Carolina at Chapel Hill   (United States)

Author keywords

Clinical trials; Phase I; Phase II

Indexed keywords

ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE BURDEN; DRUG INDUSTRY; DRUG RESEARCH; ENDOCRINE DISEASE; HUMAN; IMMUNE DEFICIENCY; INFECTION; MEDICAL PARAMETERS; METABOLIC DISORDER; MORTALITY; NEUROLOGIC DISEASE; NUTRITIONAL DISORDER; PARASITOSIS; PRIORITY JOURNAL; PUBLICATION; RESOURCE ALLOCATION; SENSORY DYSFUNCTION; COST OF ILLNESS; HEALTH;

NEW DRUG;

CLINICAL TRIALS AS TOPIC; COST OF ILLNESS; DRUG INDUSTRY; DRUGS, INVESTIGATIONAL; GLOBAL HEALTH; HUMANS;

EID: 84906094329     PISSN: 17528054     EISSN: 17528062     Source Type: Journal    
DOI: 10.1111/cts.12163     Document Type: Article

References (10)

1. Angell M. The Truth About the Drug Companies: How They Deceive Us and What To Do About It. New York: Random House; 2004.
2. Croghan TW, Pittman PM. The medicine cabinet: what's in it, why, and can we change the contents? Health Aff. 2004; 23(1): 23-33.
3. Gagne JJ, Choudhry NK. How many me-too drugs is too many? JAMA. 2011; 305(7): 711-712.
4. Isaakidis P, Swingler GH, Pienaar E, Volmink J, Ioannidis JPA. Relation between burden of disease and randomised evidence in sub-Saharan Africa: survey of research. BMJ. 2002; 324: 1-5.
5. Trouiller P, Olliaro P, Torreele E, Orbinski J, Laing R, Ford N. Drug development for neglected diseases: a deficient market and a public-health policy failure. Lancet. 2002; 359: 2188-2194.
6. Perel P, Miranda JJ, Ortiz Z, Casa JP. Relation between the global burden of disease and randomized clinical trials conducted in Latin America published in the five leading medical journals. PLoS One. 2008; 3(2): e1696.
7. Dorsey ER, Thompson JP, Carrasco M, de Roulet J, Vitticore P, Nicholson S, Johnston SC, Holloway RG, Moses H. Financing of U.S. biomedical research and new drug approvals across therapeutic areas. PLoS One. 2009; 4(9): e7015.
8. World Health Organization (WHO). The Global Burden of Disease: 2004 Update. Geneva: World Health Organization (WHO); 2008.
9. DiMasi JA, Feldman L, Seckler A, Wilson A. Trends in risks associated with new drug development: success rates for investigational drugs. Clin. Pharmacol. Ther. 2010; 87(3): 272-277.
10. Heger M. Clinical trials website struggles to serve as research data hub. Nat Med. 2012; 18(6): 837.